Bart Filius Joins Galapagos as CFO
News Oct 18, 2014
Galapagos NV has announced that Bart Filius, currently Vice President, CFO Sanofi Europe, will join Galapagos as Chief Financial Officer, effective 1 December 2014.
Bart Filius has over 13 years' experience at Sanofi. During the past three years as CFO Sanofi Europe, Bart was instrumental in transforming the Sanofi European organization to be well-positioned beyond the patent cliff.
Earlier at Sanofi, Bart was CFO and Country Manager of Sanofi in the Netherlands. Before that, he was Vice President for Mergers & Acquisitions, during which time Bart led and completed the divestiture of various franchises.
Prior to joining Sanofi, Bart was a strategy consultant at Arthur D. Little. Bart is a Dutch national and has an MBA degree from INSEAD and a bachelor's degree in business from Nyenrode University.
"We are pleased to welcome Bart Filius into our Executive team," said Onno van de Stolpe, CEO of Galapagos. "His vast experience in Big Pharma and his sharp strategic view will help us bring Galapagos to the next level, as we prepare to have our rheumatoid arthritis molecule GLPG0634 enter Phase 3 and progress more programs into patients next year."
"I am very excited to join Galapagos at this important point of its development", said Bart Filius. "As we move forward and the pipeline matures further, I look forward to bringing my experience in Finance and M&A to Galapagos."
Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line TreatmentNews
The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.READ MORE
Diabetes Drug Could Be Re-purposed to Help End Transplant RejectionNews
A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs.READ MORE
Study Shows Cancer Patients Are Choosing Less Severe Side Effects Over Treatment EfficacyNews
When choosing their preferred treatment, people with chronic lymphocytic leukemia (CLL) place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for a reduced risk of serious adverse events according to a new study.READ MORE